Minerva Neurosciences, Inc.

Enyo Pharma

Sandra Werner

Masahiro Okuyama

Remy Henri Luthringer

Nadine Noel

Jay Saoud

Emmanuelle Georgi

Florent Schmitt

Julien Leroudier

Nicolas Philippon

Diane Sampson

Françoise Richard-Tiberghien

Jacky Vonderscher

Raphaël Darteil

Joël Vacus

Hans Maag

Remy Luthringer

This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I): or a pharmaceutically acceptable salt and/or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are useful in reducing the risk of QT prolongation in a subject and in treating a disorder in a subject in need thereof, e.g., a subject diagnosed with schizophrenia, for example, in treating the negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype.

Gastro-resistant controlled release oral dosage forms

An L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and forms thereof are provided. Also provided are pharmaceutical or veterinary compositions comprising this L-lysine salt and their use for treating a number of diseases.

L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof

The present disclosure relates to compounds of Formula (I): and their prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of their preparation. The compounds disclosed herein are useful for modulating Sigma receptors and have antiviral activity, and may also be useful in the treatment and/or prevention of pain disorders, neurological disorders (e.g., Parkinson's disease and Alzheimer's disease), and cancer.

Sigma ligand compounds and uses thereof

The disclosure provides a novel polymorph of Compound (I): 2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I).HCl.2HO. Pharmaceutical compositions comprising Form (A) of Compound (I).HCl.2HO and related methods of treatment are also disclosed.

Compositions and methods for treating schizophrenia

The disclosure provides a novel polymorph of Compound (I): 2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl) methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I)&#x2022;HC1&#x2022;2HO. Pharmaceutical compositions comprising Form (A) of Compound (I)&#x2022;HC1&#x2022;2HO and related methods of treatment are also disclosed.

Growing community of inventors

Ostwald, France

Sandra Werner